References
1. Flores-Arriaga, J., et al., Prevalence and description of disorders of gut-brain interaction in Spain according to the results of the Rome Foundation Global Epidemiology Study. Neurogastroenterol Motil, 2023. 35(6): p. e14582.
2. Rezaie, A., et al., Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol, 2017. 112(5): p. 775-784.
3. Hammer, H.F., et al., European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United European Gastroenterol J, 2022. 10(1): p. 15-40.
4. Ghoshal, U.C., et al., Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association. Indian J Gastroenterol, 2022. 41(5): p. 483-507.
5. Pimentel, M., et al., ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol, 2020. 115(2): p. 165-178.
6. Martín Domínguez, V., C. Malagelada, and C. Santander, Small intestinal bacterial overgrowth. A position paper of ASENEM-SEPD. Rev Esp Enferm Dig, 2023. 115(12): p. 679-681.
7. Kashyap, P., et al., Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS). Neurogastroenterol Motil, 2024. 36(6): p. e14817.
8. Lee, C., et al., The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis. J Neurogastroenterol Motil, 2017. 23(3): p. 349-362.
9. Esterita, T., et al., Association of Functional Dyspepsia with Depression and Anxiety: A Systematic Review. J Gastrointestin Liver Dis, 2021. 30(2): p. 259-266.
10. Vasant, D.H., et al., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 2021. 70(7): p. 1214-1240.
11. Maric, S., et al., Citrulline, Biomarker of Enterocyte Functional Mass and Dietary Supplement. Metabolism, Transport, and Current Evidence for Clinical Use. Nutrients, 2021. 13(8).
12. Wu, W., et al., Ghrelin in Focus: Dissecting Its Critical Roles in Gastrointestinal Pathologies and Therapies. Curr Issues Mol Biol, 2024. 46(1): p. 948-964.
13. Klooker, T.K., et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut, 2010. 59(9): p. 1213-21.
14. Decraecker, L., et al., Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial. Gut, 2024. 73(3): p. 459-469.
15. Linsalata, M., et al., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterol, 2018. 18(1): p. 167.
16. Prospero, L., et al., Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier. Nutrients, 2021. 13(7).
17. Logan, M., et al., Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn's disease. BMC Gastroenterol, 2022. 22(1): p. 260.
18. Wouters, M.M., et al., Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology, 2016. 150(4): p. 875-87.e9.
19. Drossman, D.A. and W.L. Hasler, Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology, 2016. 150(6): p. 1257-61.
20. Almansa, C., et al., Translation, cultural adaptation and validation of a Spanish version of the Irritable Bowel Syndrome Severity Score. Rev Esp Enferm Dig, 2011. 103(12): p. 612-8.
21. Zigmond, A.S. and R.P. Snaith, The hospital anxiety and depression scale. Acta Psychiatr Scand, 1983. 67(6): p. 361-70.
22. Nahon, S., et al., Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis, 2012. 18(11): p. 2086-91.
23. Mearin, F., et al., Bowel Disorders. Gastroenterology, 2016.
24. Sperber, A.D., Highlights of the Findings From the Rome Foundation Global Epidemiology Study. Gastroenterol Hepatol (N Y), 2023. 19(9): p. 564-567.
25. Mishima, Y. and S. Ishihara, Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome. Int J Mol Sci, 2020. 21(22).
26. Arasaradnam, R.P., et al., Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut, 2018. 67(8): p. 1380-1399.
27. Savarino, E., et al., Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J, 2022. 10(6): p. 556-584.
28. Lacy, B.E., et al., ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol, 2021. 116(1): p. 17-44.
29. Pimentel, M., E.J. Chow, and H.C. Lin, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol, 2003. 98(2): p. 412-9.
30. Black, C.J., et al., Functional gastrointestinal disorders: advances in understanding and management. Lancet, 2020. 396(10263): p. 1664-1674.
31. Chen, M., et al., Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne), 2022. 13: p. 817100.
32. Maroto, C., et al., Plasma levels of intestinal fatty-acid binding protein (I-FABP), abdominal distension and hydrogen concentration after lactitol small intestinal bacterial overgrowth (SIBO) test. Rev Esp Enferm Dig, 2023. 115(12): p. 727-728.
33. Mir, B.A., et al., Emerging Biomarkers for Screening and Management of Celiac Disease. Biomed Res Int, 2022. 2022: p. 2756242.
34. Saad, R.J. and W.D. Chey, Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol, 2014. 12(12): p. 1964-72; quiz e119-20.
35. Lacy, B.E., D. Cangemi, and M. Vazquez-Roque, Management of Chronic Abdominal Distension and Bloating. Clin Gastroenterol Hepatol, 2021. 19(2): p. 219-231.e1.